Vera Therapeutics, Inc.

NASDAQ:VERA

Biotechnology

Healthcare
$25.58 +0.27%

+$0.09 today

Market cap
$1.85B
Beta
0.95
P/E (TTM)
-6.8
EPS (TTM)
-$5.16
52W Low $19.07High $56.05

Volume 0.95M

Average 1.18M

VERA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Vera Therapeutics, Inc.NASDAQ: VERA

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$107.49M, compared with -$74.54M a year earlier. Trailing-twelve-month EBITDA was -$393.82M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -101.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$107.49M+9.7% QoQ
Last fiscal yearDec 2025
-$291.62M-101.9% YoY
LTMJun 2026
-$393.82M-87.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.2%+100.0%+144.2 pp
1 year-101.9%+100.0%+201.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(291.62M) USD
Year-over-year change
-101.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How VERA compares with its peers on the latest reported figures

  • VERA's LTM Jun 2026 EBITDA of -$393.82M is the 8th highest of the 10 companies compared; the peer median is -$70.61M.
  • Its year-over-year change of -87.1% is the lowest of 10, against a peer median of +24.1%.
VERA Competitors Peer median
EBITDA for VERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$58.49M +176.6%—25.2%
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$43.43M +163.2%—9.4%
PHARPharming Group N.V.LTM Mar 2026$39.48M +82.4%-1.9%10.7%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$29.53M +74.2%—1550.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M -31.5%—843.9%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$153.62M -5.2%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$245.81M -69.1%——
VERAVera Therapeutics, Inc.LTM Jun 2026-$393.82M -87.1%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$442.87M -9.5%—5986.3%
BHVNBiohaven Ltd.LTM Jun 2026-$574.94M +24.1%——
Peer median (excluding VERA) -$70.61M+24.1%-1.9%434.6%

Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0(846K)000
Gross Profit0846K000
Gross Margin—————
Research & Development22.48M69.84M78.23M126.17M215.26M
Selling, General & Admin11.92M21.91M23.79M41M100.22M
Operating Expenses34.4M91.75M102.01M167.17M315.47M
Depreciation & Amortization176K(846K)21K105K468K
EBITDA(32.41M)(88.91M)(92.18M)(144.42M)(291.62M)
EBITDA Margin—————
Operating Income(34.4M)(90.9M)(102.01M)(167.17M)(315.47M)
Operating Margin—————
Interest Income15K1.75M7.98M20.71M24.48M
Interest Expense20K992K3.79M7.63M7.53M
Other Income / Expenses1.79M1.85M6.02M15.02M15.86M
Income Before Tax(32.61M)(89.06M)(95.99M)(152.15M)(299.61M)
Pre-Tax Margin—————
Income Tax Expense1K1K1K1K1K
Net Income(32.61M)(89.06M)(95.99M)(152.15M)(299.62M)
Net Margin—————
EPS (Basic)(2.43)(3.35)(2.25)(2.75)(4.66)
EPS (Diluted)(2.43)(3.35)(2.25)(2.75)(4.66)
Weighted Avg Shares13.44M26.57M42.71M55.33M64.23M
Weighted Avg Shares (Diluted)13.44M26.57M42.71M55.33M64.23M

Vera Therapeutics, Inc.

NASDAQ:VERA

Intrinsic Alpha fair value

Locked

Current Price

$25.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.